Photo Illustration by Thomas Levinson/The Daily Beast/Getty/Wikimedia CommonsWhen Kentucky Attorney General Daniel Cameron announced this year that his office planned to take at least $42 million from state money and use it to fund corporate research for an experimental psychedelic addiction treatment, he caught many people off guard—including some of the officials tasked with allocating that money.The proposal—to fund development for the alternative therapy ibogaine—and the continuing mystery o
The inside story about a state commission that wants to spend $42 million on a controversial psychedelic drug to treat opioid addiction and the complicated reasons why.
The American Psychedelic Practitioners Association (APPA), a federal organization with the goal of safely integrating psychedelics into the U.S. healthcare system, has retained The Daschle Group as governmental affairs counsel.